Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of EPA NIKP Soft Cap versus EPADEL S900 in healthy Thai adults under fed conditions
TCTR20260405008Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eicosapentaenoic acid (2 arms), sponsored by Bio-innova. Primary endpoints: Maximum plasma concentration (Cmax), AUC0-t and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
eicosapentaenoic acid
Beyond the preview
Go deeper on TCTR20260405008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260405008.